{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:08:34Z","timestamp":1762898914314},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T00:00:00Z","timestamp":1366243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatology Research"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:p>The introduction of molecularly targeted drugs has increased the risk of reactivation of hepatitis <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content> virus (<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>), which is a potentially fatal complication following anticancer chemotherapy even in patients who have previously resolved their <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content> infection. <jats:styled-content style=\"fixed-case\">CC<\/jats:styled-content> chemokine receptor 4 (<jats:styled-content style=\"fixed-case\">CCR4<\/jats:styled-content>) has been identified as a novel molecular target in antibody therapy for patients with adult <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\u2010cell leukemia\u2013lymphoma (<jats:styled-content style=\"fixed-case\">ATL<\/jats:styled-content>) and peripheral <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\u2010cell lymphoma, and the humanized anti\u2010<jats:styled-content style=\"fixed-case\">CCR4<\/jats:styled-content> monoclonal antibody mogamulizumab has been developed. We reported <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content> reactivation of an <jats:styled-content style=\"fixed-case\">ATL<\/jats:styled-content> patient with previously resolved <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content> infection after mogamulizumab treatment in a dose\u2010finding study for this antibody. Our retrospective analysis using preserved samples also revealed the detailed kinetics of <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content> levels before and just after <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content> reactivation.<\/jats:p>","DOI":"10.1111\/hepr.12117","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T12:32:33Z","timestamp":1364301153000},"page":"354-357","source":"Crossref","is-referenced-by-count":26,"title":["Reactivation of hepatitis <scp>B<\/scp> virus in a patient with adult <scp>T<\/scp>\u2010cell leukemia\u2013lymphoma receiving the anti\u2010<scp>CC<\/scp> chemokine receptor 4 antibody mogamulizumab"],"prefix":"10.1111","volume":"44","author":[{"given":"Nobuaki","family":"Nakano","sequence":"first","affiliation":[{"name":"Department of Hematology Imamura Bun\u2010in Hospital  Kagoshima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Virology and Liver Unit Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology Imamura Bun\u2010in Hospital  Kagoshima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifusa","family":"Takatsuka","sequence":"additional","affiliation":[{"name":"Department of Hematology Imamura Bun\u2010in Hospital  Kagoshima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Akinaga","sequence":"additional","affiliation":[{"name":"Kyowa Hakko Kirin.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Mizokami","sequence":"additional","affiliation":[{"name":"The Research Center for Hepatitis and Immunology National Center for Global Health and Medicine  Ichikawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuzo","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Tumor Immunology Aichi Medical University School of Medicine  Aichi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Department of Hematology Imamura Bun\u2010in Hospital  Kagoshima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,4,18]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90599-G"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200101043440120"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.04.015"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.0182"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0359-5"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25253"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-011-0941-5"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2697"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3575"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3472"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0624-x"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2012.01105.x"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2012.00998.x"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"e_1_2_5_16_1","doi-asserted-by":"crossref","first-page":"abstract 2641","DOI":"10.1182\/blood.V120.21.2641.2641","article-title":"Prospective nationwide observational study of hepatitis B virus (HBV) DNA monitoring and preemptive antiviral therapy for HBV reactivation in patients with B\u2010cell non\u2010Hodgkin lymphoma following rituximab containing chemotherapy: results of interim analysis","volume":"120","author":"Kusumoto S","year":"2012","journal-title":"Blood"}],"container-title":["Hepatology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhepr.12117","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hepr.12117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T22:47:37Z","timestamp":1696286857000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hepr.12117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,18]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/hepr.12117"],"URL":"https:\/\/doi.org\/10.1111\/hepr.12117","archive":["Portico"],"relation":{},"ISSN":["1386-6346","1872-034X"],"issn-type":[{"value":"1386-6346","type":"print"},{"value":"1872-034X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,18]]}}}